Case number 1:25-cv-00523
Boehringer Ingelheim Pharmaceuticals Inc. et al v. Biocon Limited et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Oct 28, 2025 | 24 | CONSENT JUDGMENT. Signed by Judge Colm F. Connolly on 10/28/2025. (mws) (Entered: 10/28/2025) (4) |
| Oct 28, 2025 | N/A | CASE CLOSED per D.I. 24 . (mws) (Entered: 10/28/2025) (0) |
| Oct 28, 2025 | 25 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,853,156 B2; 9,486,526 B2; 10,034,877 B2; 11,911,388 B2. (Attachments: # 1 Consent Judgment) (mws) (Entered: 10/28/2025) (0) |
| Oct 24, 2025 | 23 | PROPOSED CONSENT JUDGMENT by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Dellinger, Megan) (Entered: 10/24/2025) (4) |
| Sep 24, 2025 | 22 | SO ORDERED, re 21 STIPULATION TO EXTEND TIME for Defendants Biocon Limited, Biocon Pharma, Inc. and Biocon Pharma Limited's initial disclosures pursuant to Federal Rule of Civil Procedure 26(a)(1) and to produce an up to date version of Biocon's ANDA No. 220117 and any related FDA correspondence to September 29, 2025, filed by Biocon Limited, Biocon Pharma, Inc., Biocon Pharma Limited. Signed by Judge Colm F. Connolly on 9/24/2025. (kmd) (Entered: 09/24/2025) (2) |
| Sep 19, 2025 | 21 | STIPULATION TO EXTEND TIME for Defendants Biocon Limited, Biocon Pharma, Inc. and Biocon Pharma Limited's initial disclosures pursuant to Federal Rule of Civil Procedure 26(a)(1) and to produce an up to date version of Biocon's ANDA No. 220117 and any related FDA correspondence to September 29, 2025 - filed by Biocon Limited, Biocon Pharma Limited, Biocon Pharma, Inc.. (Taylor, Daniel) (Entered: 09/19/2025) (2) |
| Sep 18, 2025 | 19 | STIPULATION TO EXTEND TIME for the parties to submit a proposed Protective Order to October 9, 2025 - filed by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Dellinger, Megan) (Entered: 09/18/2025) (2) |
| Sep 18, 2025 | 20 | SO ORDERED, re 19 STIPULATION TO EXTEND TIME for the parties to submit a proposed Protective Order to October 9, 2025, filed by Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim International GmbH. Signed by Judge Colm F. Connolly on 9/18/2025. (kmd) (Entered: 09/18/2025) (2) |
| Sep 12, 2025 | 18 | SO ORDERED, re 17 STIPULATION TO EXTEND TIME for Biocon Limited, Biocon Pharma, Inc. and Biocon Pharma Limited's Initial Disclosures pursuant to Federal Rule of Civil Procedure 26(a)(1) to September 17, 2025, filed by Biocon Limited, Biocon Pharma, Inc., Biocon Pharma Limited. Signed by Judge Colm F. Connolly on 9/12/2025. (kmd) (Entered: 09/12/2025) (2) |
| Sep 11, 2025 | 17 | STIPULATION TO EXTEND TIME for Biocon Limited, Biocon Pharma, Inc. and Biocon Pharma Limited's Initial Disclosures pursuant to Federal Rule of Civil Procedure 26(a)(1) to September 17, 2025 - filed by Biocon Limited, Biocon Pharma Limited, Biocon Pharma, Inc.. (Taylor, Daniel) (Entered: 09/11/2025) (2) |
| Sep 10, 2025 | 16 | NOTICE OF SERVICE of (1) Plaintiffs' Initial Disclosures Pursuant to Fed. R. Civ. P. 26(a)(1); and (2) Plaintiffs' Preliminary Disclosure of Asserted Claims filed by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc..(Dellinger, Megan) (Entered: 09/10/2025) (3) |
| Aug 19, 2025 | 15 | SCHEDULING ORDER: Joinder of Parties due by 9/14/2026. Amended Pleadings due by 9/14/2026. Fact Discovery completed by 9/21/2026. Expert Discovery due by 2/10/2027. Joint Claim Construction Brief due by 4/22/2026. A Markman Hearing is set for 6/18/2026 at 09:00 AM in Courtroom 4B before Judge Colm F. Connolly. Proposed Pretrial Order due by 3/22/2027. A Final Pretrial Conference is set for 4/12/2027 at 02:00 PM in Courtroom 4B before Judge Colm F. Connolly. A 5-day Bench Trial is set to begin 4/19/2027 at 08:30 AM in Courtroom 4B before Judge Colm F. Connolly. Signed by Judge Colm F. Connolly on 8/19/2025. (mws) (Entered: 08/19/2025) (27) |
| Aug 19, 2025 | N/A | Remark: The August 20, 2025 Scheduling Conference is cancelled per the filing and entry of a scheduling order with no areas of dispute. (mws) (Entered: 08/19/2025) (0) |
| Aug 18, 2025 | 14 | PROPOSED ORDER -- Scheduling Order -- re 13 Order Setting Scheduling Conference, by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Letter to The Honorable Colm F. Connolly)(Dellinger, Megan) (Entered: 08/18/2025) (0) |
| Jul 30, 2025 | 13 | Order Setting Telephonic Scheduling Conference: A Telephonic Scheduling Conference is set for 8/20/2025 at 03:00 PM before Judge Colm F. Connolly. If the parties have no disputes about the scheduling order, the Court will not require the parties to appear at a conference. Signed by Judge Colm F. Connolly on 7/30/2025. (mws) (Entered: 07/30/2025) (1) |
| Jul 28, 2025 | 11 | ANSWER to 1 Complaint, filed by Biocon Limited, Biocon Pharma Limited, Biocon Pharma, Inc..(Taylor, Daniel) (Entered: 07/28/2025) (30) |
| Jul 28, 2025 | 12 | Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Biocon Limited, Biocon Pharma Limited, Biocon Pharma, Inc.. (Belgam, Neal) (Entered: 07/28/2025) (2) |
| Jun 6, 2025 | 8 | WAIVER OF SERVICE returned executed by Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG: For Biocon Limited waiver sent on 5/29/2025, answer due 7/28/2025. (Dellinger, Megan) (Entered: 06/06/2025) (1) |
| Jun 6, 2025 | 9 | WAIVER OF SERVICE returned executed by Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG: For Biocon Pharma, Inc. waiver sent on 5/29/2025, answer due 7/28/2025. (Dellinger, Megan) (Entered: 06/06/2025) (1) |
| Jun 6, 2025 | 10 | WAIVER OF SERVICE returned executed by Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG: For Biocon Pharma Limited waiver sent on 5/29/2025, answer due 7/28/2025. (Dellinger, Megan) (Entered: 06/06/2025) (1) |
| May 7, 2025 | N/A | Case Assigned to Judge Colm F. Connolly. Please include the initials of the Judge (CFC) after the case number on all documents filed. (nmf) (Entered: 05/07/2025) (0) |
| May 7, 2025 | 7 | STANDING ORDER REGARDING BRIEFING IN ALL CASES (mws) (Entered: 05/07/2025) (2) |
| Apr 30, 2025 | 1 | COMPLAINT against Biocon Limited, Biocon Pharma Limited, Biocon Pharma, Inc. (Filing fee $ 405, receipt number ADEDC-4675022) - filed by Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG. (Attachments: # 1 Exhibits 1-4, # 2 Civil Cover Sheet)(jfm) (Entered: 04/30/2025) (0) |
| Apr 30, 2025 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (jfm) (Entered: 04/30/2025) (3) |
| Apr 30, 2025 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 03/18/2025. Date of Expiration of Patent: See Attached.Thirty Month Stay Deadline: 9/18/2027. (jfm) (Entered: 04/30/2025) (1) |
| Apr 30, 2025 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,853,156 B2; 9,486,526 B2; 10,034,877 B2; 11,911,388 B2. (jfm) (Entered: 04/30/2025) (1) |
| Apr 30, 2025 | 5 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent C. H. Boehringer Sohn AG & Co. KG for Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharmaceuticals Inc. filed by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. (jfm) (Entered: 04/30/2025) (2) |
| Apr 30, 2025 | 6 | Summons Issued as to Biocon Limited, Biocon Pharma Limited, and Biocon Pharma, Inc. on 4/30/2025. (Attachments: # 1 Summons Issued, Biocon Pharma Limited, # 2 Summons Issued, Biocon Pharma, Inc.)(jfm) (Entered: 04/30/2025) (0) |
